Semaglutide (Ozempic, Wegovy): Evidence and What Users Report
Also known as:
often mentioned with:
Related topics
Report
community guides:
Canada:
Canada & reports:
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist sold as Ozempic (type 2 diabetes injection), Wegovy (weight-management injection and pill) and Rybelsus (diabetes pill). It mimics the gut hormone GLP-1, slowing stomach emptying and reducing appetite. What is GLP-1? explains the hormone.
What the trials show
In STEP 1, adults with obesity lost about 15% of body weight on average over 68 weeks with Wegovy-strength semaglutide, vs about 2% with placebo. In the SURMOUNT-5 head-to-head trial, average loss was 13.7% with semaglutide vs 20.2% with tirzepatide at 72 weeks (Zepbound vs Wegovy).
In SELECT, 17,604 adults with overweight or obesity and existing heart disease (without diabetes) had a 20% lower risk of heart attack, stroke or cardiovascular death on semaglutide vs placebo. In the STEP 1 extension, people who stopped regained about two-thirds of the weight they had lost within a year.
Safety: gastrointestinal effects are the most common reason people stop. Labels warn about pancreatitis, gallbladder disease and thyroid C-cell tumours in rodents, and in 2025 the European Medicines Agency listed NAION, an optic-nerve condition, as a very rare side effect. Last reviewed: October 2026.
What semaglutide confessions describe
Regain after stopping is the most repeated story. One writer took it for 14 months and says they "gained it all back in 4" (#57); another quit after 11 months and 65 lbs and says the food noise came back within three weeks (#87).
Switching is the second theme. Several writers moved to tirzepatide or retatrutide after a stall, saying semaglutide made overeating feel miserable rather than removing hunger (#384, #194, #668). Others describe the full GI picture of nausea, vomiting, constipation and burping (#298), and one attributes major hair shedding to the rapid weight loss (#43).
These are anonymous personal accounts, not incidence data.
more topics on these reports:
Anonymous semaglutide reports
If you have used semaglutide, including stopping or switching, submit what actually happened.
Submit yoursCommunity Q&A
- How much weight do people lose on semaglutide?
- In STEP 1, average loss was about 15% of body weight over 68 weeks vs about 2% with placebo. Individual results vary widely.
- What happens when you stop semaglutide?
- In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping. Regain is also the most common theme in confessions here.
- Is semaglutide or tirzepatide better for weight loss?
- In the SURMOUNT-5 head-to-head trial, tirzepatide produced more average weight loss (20.2% vs 13.7%). Tolerability, coverage and medical history also matter.
- Is this page a semaglutide dosing guide?
- No. This is not a dosing recommendation. The site does not name or recommend suppliers.
- What does semaglutide do to your pancreas?
- It boosts glucose-dependent insulin release from the pancreas. The label warns about acute pancreatitis; stop and seek care for severe, persistent abdominal pain.
- What organ is Ozempic hard on?
- Label warnings cover the pancreas (pancreatitis), gallbladder (gallstones), kidneys (injury from dehydration after vomiting or diarrhea) and a boxed warning about thyroid C-cell tumours seen in rodents.
- How does Ozempic affect A1C?
- In the SUSTAIN 7 trial, semaglutide lowered HbA1c by 1.5 to 1.8 percentage points over 40 weeks in adults with type 2 diabetes.
Sources
- STEP 1 — Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021
- SURMOUNT-5 — Aronne et al., Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025
- SELECT — Lincoff et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023
- SUSTAIN 7 — Pratley et al., Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018
- Zepbound (tirzepatide) prescribing information — DailyMed (NLM)
- Wegovy (semaglutide) prescribing information — DailyMed (NLM)
- Ozempic (semaglutide) prescribing information — DailyMed (NLM)
- EMA PRAC meeting highlights, 2–5 June 2025 (semaglutide and NAION)
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.